Personalized Cancer Vaccine Boosts Recurrence-Free Survival in Melanoma
Clinical implications apply to virtually all solid tumors and possibly hematologic malignancies
Stay updated with breaking news from Ryan Sullivan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Clinical implications apply to virtually all solid tumors and possibly hematologic malignancies
The mRNA cancer vaccine combined with immunotherapy improved survival rates for stage 3 and 4 melanoma, Moderna and Merck announced. Here's what to know.
The addition of a personalized cancer vaccine to Keytruda led to a 44% reduction in the risk of death or recurrence in certain patients with melanoma.
Combining Moderna's patient-specific mRNA-based cancer vaccine with pembrolizumab may prolong recurrence-free survival in patients with high-risk melanoma vs pembrolizumab alone, new data show.
The mRNA cancer vaccine combined with immunotherapy improved survival rates for stage 3 and 4 melanoma, Moderna and Merck announced. Here's what to know.